Skip to main content
OpenTrials
Completed

NCT Number: NCT04985799

Comparing KIM to TVT Exact Sling

To assess to the non-inferiority of the retropubic Neomedic Knotless Incontinence Mesh (KIM) sling compared to the Gynecare Tension-free Vaginal Tape (TVT) Exact sling.

Participants: Women 21 years or older with a diagnosis of stress urinary incontinence (SUI) or mixed urinary incontinence (MUI) with objective evidence of SUI planning surgery for stress urinary incontinence.

Procedures (methods): Patients will be randomized to receive either the Gynecare TVT Exact sling or the retropubic Neomedic KIM sling. Patients will be followed for 1 year postoperatively.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

UNC Hospitals Hillsborough Campus, Hillsborough, North Carolina, United States

Loading trial locations.

About this study

Midurethral slings (MUS) are recognized as a minimally invasive treatment of SUI. The retropubic route of MUS placement has a cure rate of 89.1% with long term subjective cure rates ranging from 51-88%. The Neomedic Knotless Incontinence Mesh (KIM) sling is a tension-free macroporous monofilament polypropylene knotless mesh designed to be resistant to elongation and deformation over time. The KIM sling also offers a reusable trocar, which results in less waste and cost- savings. KIM sling trocars are available for the retropubic route or trans-obturator (TOT) route.

While studies have been performed comparing the TOT approach of the KIM sling to other slings, no studies have been performed to date with the retropubic (RP) approach. The RP and TOT approaches to MUS have been shown to be equivalent in the treatment of SUI. Since the same mesh material of the KIM sling is used for both the TOT and RP approach, it can be hypothesis that the RP route would show similar treatment success rates.

A type 1 macroporous (> 75um) polypropylene mesh is the most appropriate material for vaginal implantation. However, literature has suggested that the design and weave of synthetic mesh material can also have a significant effect on efficacy and safety; therefore, the novel design of the KIM may be beneficial to reduce complications. If there is similar efficacy with the RP approach of the KIM sling to the TVT Exact, there will be benefit of reduced costs and the potential for less complications. With this study, the objective is to show non-inferiority of the KIM sling to the Gynecare TVT Exact.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women greater than or equal to 21 years based on medical chart review
  • Diagnosis of SUI or mixed urinary incontinence based on medical chart review
  • Objective evidence of SUI as indicated by positive cough stress test or urodynamic stress incontinence during urodynamic testing within the last year prior to enrollment. Medical chart will be reviewed.
  • Planning surgery for SUI with/without pelvic organ prolapse (POP) surgery

Exclusion criteria

  • Current pregnancy, desire for future childbearing, less than or equal to 12 months postpartum at the time of enrollment
  • Prior history of surgery for SUI based on medical chart review
  • Bladder capacity <200 mL on Urodynamic testing or post-void residual (PVR) >150 mL on urodynamic testing or bladder scan.
  • Non-ambulatory
  • Current genitourinary fistula or urethral diverticulum based on pre-operative exam in the medical chart.

Treatment and study plan

Gynecare TVT Exact Continence System

Device

Participants will have placement of Gynecare TVT Exact sling.

Other names: Midurethral sling

Neomedic KIM (Knotless Incontinence Mesh)

Device

Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling

Other names: Midurethral sling

Primary outcomes

  1. Number of Participants With Treatment Success at 6 Weeks After Surgery

    Time frame: 6 weeks after surgery

    Treatment success is defined by a composite outcome of 1) response of No or "no bother" to question #3 on urogenital distress inventory-6 (UDI-6) validated questionnaire AND no retreatment of stress incontinence.

Secondary outcomes

  1. Number of Participants With Treatment Success at 1 Year After Surgery

    Time frame: up to 1 year

    Treatment success is defined by a composite outcome of 1) response of No or "no bother" to question #3 on urogenital distress inventory-6 (UDI-6) validated questionnaire AND no retreatment of stress incontinence.

  2. Number of Participants Requiring Reoperation for Mesh Complications or Urinary Retention Thru 1 Year After Surgery

    Time frame: up to 1 year

    Reoperation for mesh complications or urinary retention thru 1 year after initial sling surgery

  3. Number of Participants With Mesh Exposure Thru 1 Year After Surgery

    Time frame: up to 1 year after surgery

    Sling mesh exposure identified on examination thru 1 year after surgery

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Registry information

Official study title

A Randomized Controlled Trial Comparing Retropubic KIM Sling to TVT Exact Midurethral Sling

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Aug 2, 2021
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.